CuraTeQ Biologics Private Limited

Wholly owned biopharmaceutical subsidiary of Aurobindo Pharma, headquartered in Hyderabad and dedicated to biosimilars in oncology, immunology, respiratory and ophthalmology. It covers end to end from drug substance through fill and finish, with an integrated 60,000-litre mammalian cell culture facility. It has four approved and launched biosimilars: filgrastim, pegfilgrastim, trastuzumab and bevacizumab.